CLSD Clearside Biomedical Inc.

1.2
0  0%
Previous Close 1.2
Open 1.21
Price To Book 2.79
Market Cap 45114661
Shares 37,595,551
Volume 286,870
Short Ratio
Av. Daily Volume 544,952

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released May 31, 2018 - mixed data. 12.3 ETDRS letters compared to 13.5 ETDRS letters in control arm.
Suprachoroidal CLS-TA - TYBEE
Diabetic Macular Edema (DME)
Phase 3 data released November 5, 2018 did not meet primary endpoint.
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
PDUFA date October 19, 2019.
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis

Latest News

  1. Edited Transcript of CLSD earnings conference call or presentation 8-May-19 12:30pm GMT
  2. Clearside Biomedical to Present at the UBS Global Healthcare Conference
  3. Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update
  4. Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings
  5. Clearside Biomedical to Report First Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, May 8, 2019
  6. Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings
  7. Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEO
  8. Clearside Biomedical to Present at the 18th Annual Needham Healthcare Conference
  9. Edited Transcript of CLSD earnings conference call or presentation 12-Mar-19 9:00pm GMT
  10. Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  11. Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference
  12. Clearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019
  13. Do Insiders Own Shares In Clearside Biomedical, Inc. (NASDAQ:CLSD)?
  14. Four Tech Stocks Bubbling with Excitement
  15. Recent Analysis Shows Cisco, Zendesk, Clearside Biomedical, Conn's, NIC, and Commercial Vehicle Group Market Influences — Renewed Outlook, Key Drivers of Growth
  16. Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019
  17. Clearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society
  18. Healthcare Companies Positioned in Major Markets
  19. Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
  20. Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference